STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual MeetingGlobeNewsWire • 04/17/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSOPRNewsWire • 01/31/24
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant PatientsGlobeNewsWire • 01/17/24
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board RecommendationGlobeNewsWire • 12/28/23
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR RegistryGlobeNewsWire • 09/27/23
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial OfficerGlobeNewsWire • 09/19/23
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ TransplantationGlobeNewsWire • 09/11/23
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D'AmicoGlobeNewsWire • 09/01/23
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in BrazilGlobeNewsWire • 08/31/23